Search
Surrozen Inc
SRZNAdd to Watchlist
24.920USD
-0.600-2.35%
Close 07/02, 13:00（ET）Quotes delayed by 15 min
286.33MMarket Cap
LossP/E TTM
Earnings Forecast
Currency: USD Updated: 2026-07-02The current earnings forecast score of Surrozen Inc is 8.40, ranking 128 out of 387 in the Biotechnology & Medical Research industry. The average price target is 37.00, with a high of 42.00 and a low of 32.00.
Analyst Rating
Based on
5
analysts
Buy
Current Rating
42.667
Target Price
+67.19%
Upside Space
Strong Buy
Buy
Hold
Sell
Strong Sell
Peer Comparison
562
Total
5
Median
6
Average
Company name
Ratings
Analysts
Surrozen Inc
SRZN
5
CRISPR Therapeutics AG
CRSP
27
Ionis Pharmaceuticals Inc
IONS
27
Beigene Ltd
ONC
27
argenx SE
ARGX
26
IQVIA Holdings Inc
IQV
26
1
2
3
...
113
Support & Resistance
Relevant data have not been disclosed by the company yet.
Financial Forecasting
EPS
Revenue
Net Profit
EBIT
Forecast
Actual
FAQs
What is Surrozen Inc's expected revenue for the next quarter?
Surrozen Inc's expected revenue is 467.25K.
What is Surrozen Inc's price target?
Analysts forecast that Surrozen Inc's price target is USD 37.00, with the highest forecast at USD 42.00 and the lowest forecast at USD 32.00.
How have Surrozen IncSRZN's recent earnings per share performed?
The market expectation was USD -11.65, while Surrozen IncSRZN's earnings per share (EPS) for the previous quarter was USD -20.09. EPS for the next quarter is expected at USD -1.29.
What is the analyst rating for Surrozen Inc?
Based on the ratings of Surrozen Inc's stock from 5 analysts, most analysts support a Buy trend. After considering the opinions of other analysts, we ultimately rate Apple's stock as Buy. Please note that this is not trading advice. You still need to conduct your own analysis.